TXG — 10x Genomics, Inc.
Is TXG overbought or oversold? Here is the current MarketMoodz read.
10x Genomics, Inc. (TXG) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Health Information Services) last closed at $56.30. The rating moved from Strong Oversold to Oversold on November 5, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$56.30
- Last changeMoved from Strong Oversold to Oversold on November 5, 2026
- SectorHealthcare
- IndustryHealth Information Services
See all oversold Healthcare stocks →
AI analysis
10x Genomics (TXG) benefits from a strong platform position in single‑cell and spatial genomics with recurring consumables revenue and multiple growth catalysts across research and pharma. Near‑term performance will hinge on execution of instrument placements, consumables growth, and margin expansion as the company scales. Key downside exposures include competition, R&D budget cyclicality, and execution/cash risks that could pressure results or lead to dilution in weaker scenarios.
Key factors
- Market leadership in single‑cell and spatial genomics platforms with an installed base that drives recurring consumables revenue
- High-margin consumables and software/service attach rates that can convert instrument placements into predictable revenue streams
- Strong addressable market across research, pharma, and clinical translational applications with multi-year secular tailwinds for genomics
- Ongoing product innovation (spatial, immune-oncology, multiomic workflows) that expands use cases and wallet share per customer
- Potential margin expansion as commercial scale and mix shift toward consumables and software
- Partnerships and growing adoption among large biopharma customers, supporting longer-term revenue visibility
Risks
- Execution risk on instrument placements, consumables sell-through and manufacturing/supply chain disruptions
- Intensifying competition from larger, well-funded incumbents and emerging platform entrants that could compress pricing or slow adoption
- Research and commercial cyclical exposure: reduced academic and pharma R&D spend in a downturn could depress demand
- Capital requirements and potential equity dilution if cash generation is insufficient to fund growth initiatives
- Product reliability, regulatory or quality issues that could delay adoption or lead to customer churn
- High stock volatility and sentiment-driven price moves unrelated to fundamentals
See today's live rating, score and targets
Members see the live hourly rating for TXG — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.